





TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER... School of Medicine Cancer Center

## **Cell Line Data Sheet for Rh30**

Disease: Histology Subtype: Phase of Therapy: Treatment: Gender: Age at diagnosis: Race: Age at sample collection: Source of Culture: Primary Tumor Site: Date Established:	Rhabdomyosarcom Alveolar Diagnosis None Male 17 years N/A N/A Bone Marrow Posterior fossa	na		
PAX-FKHR Status: p53 functionality: Karyotype: Modal No:	Positive for translocation Functional			
R-IC50 (DIMSCAN*): *see reference 1	Vincristine (ng/ml) 0.30 ± 0.07	<u>Melphalan (µg/ml)</u> 2.05 ± 0.29	Etoposide (ng/ml) 0.19 ± 0.03	<u>Rapamycin (ng/ml)</u> 0.73 ± 0.13
Growth Conditions:	Please see Protocols section at <u>https://www.cccells.org/protocols.php</u> 5% CO <sub>2</sub> , 20% O <sub>2</sub> , 37.0°C			
Media Formulation:	Please see Protocols section at <u>https://www.cccells.org/protocols.php</u> Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)			
Doubling Time: Growth Properties:	35 hours Elongated cells and round cells, adherent with small population of suspended cells			
STR Profile:	May be obtained at <u>https://strdb.cccells.org/</u>			
Notes:	Positive for MyoD1 and myogenin			

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.

> Childhood Cancer Repository Powered by Alex's Lemonade Stand COG resource Laboratory www.cccells.org





TECH UNIVERSITY

HEALTH SCIENCES CENTER.

School of Medicine

Cancer Center


## **Cell Line Data Sheet for RH30**

## **References:**

 Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. Pediatric Blood Cancer 56: 239-249, 2011. PubMed ID: 20922763 <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/</u>

SEE NCI Pediatric Preclinical Testing Program references.

- Petak, I., Douglas, L., Tillman, D.M., Vernes, R., Houghton, J.A. (2000). Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Clin Cancer Res 6, 4119-27. PM:11051265 https://clincancerres.aacrjournals.org/content/6/10/4119.long
- Rodriguez-Perales, S., Martinez-Ramirez, A., de Andres, S.A., Valle, L., Urioste, M., Benitez, J., Cigudosa, J.C. (2004). Molecular cytogenetic characterization of rhabdomyosarcoma cell lines. Cancer Genet Cytogenet 148, 35-43. PM:14697639 <u>https://www.sciencedirect.com/science/article/pii/S0165460803002164?via%3Dihub</u>



Childhood Cancer Repository Powered by Alex's Lemonade Stand COG resource Laboratory TEXAS TECH UNIVERSITY. WWW.CCCells.org

TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER. 3/3

TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER.

TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER. School of Medicine